A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

✍ Scribed by Morschhauser, Franck; Fitoussi, Olivier; Haioun, Corinne; Thieblemont, Catherine; Quach, Hang; Delarue, Richard; Glaisner, Sylvie; Gabarre, Jean; Bosly, André; Lister, John; Li, Ju; Coiffier, Bertrand

• Book ID: 121956801
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 467 KB
• Volume: 49
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2013.04.029